HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Bouvier, G. L. Articles by Katz, A. J. Search for Related Content PubMed Articles by Le Bouvier, G. L. Articles by Katz, A. J.

Concurrently Circulating Hepatitis B Surface Antigen and Heterotypic Anti-HB_s Antibody¹

From the Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06510; and the Connecticut Red Cross Blood Program of the American National Red Cross, Farmington, Connecticut 06032

Abstract

In the early days of testing for hepatitis B surface antigen (HB₈Ag)² and the homologous antibody (anti-HB₈), there were reports of antigen and antibody co-existing in the same serum specimen (1, 2). Their subspecificities were not determined; but their homotypic character was evidently inferred, and in keeping with this idea were certain results obtained by complement fixation (3), and electronmicroscopic observations of circulating complexes apparently made up of HB₈Ag-positive Australia particles and antibody molecules (4). Some recent studies have adduced further evidence for the existence of such complexes (5), whereas others have failed to substantiate the concurrent presence of HB₈Ag and homologous anti-HB₈, at least in the blood of asymptomatic carriers of the antigen (6).

With the definition of distinct antigenic phenotypes of HB₈Ag, there arose the theoretical possibility that Australia particles of one phenotype might co-circulate with free anti-HB₈ antibody directed against antigenic configurations characteristic of a different phenotype.

Footnotes

¹ This work was supported by the United States Army Medical Research and Development Command (Contract No. DADA 17-70-C-0042), and by National Institutes of Health Biomedical Research Support Grant No. 5-S07-RR05443.

² Abbreviations used in this paper: HB₈Ag, hepatitis B surface antigen; anti-HB₈, antibody against HB₈Ag; HBV, hepatitis B virus; ID, immunodiffusion; RPHA, reversed passive hemagglutination; SGOT, serum glutamic oxalacetic transaminase.

This article has been cited by other articles:

				S. Margeridon, A. Lachaux, C. Trepo, F. Zoulim, and A. Kay A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus J. Gen. Virol., June 1, 2005; 86(6): 1687 - 1693. [Abstract] [Full Text] [PDF]